SymBio Pharmaceuticals Limited (4582.T)
JPY 154.0
(-1.28%)
JPY 154.0
(-1.28%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 15.35 Billion JPY | 47.14% |
| 2022 | 10.43 Billion JPY | 23.43% |
| 2021 | 8.45 Billion JPY | 34.72% |
| 2020 | 6.27 Billion JPY | 18.98% |
| 2019 | 5.27 Billion JPY | -15.47% |
| 2018 | 6.23 Billion JPY | 46.73% |
| 2017 | 4.25 Billion JPY | -38.18% |
| 2016 | 6.87 Billion JPY | 38.0% |
| 2015 | 4.98 Billion JPY | -33.13% |
| 2014 | 7.45 Billion JPY | -3.03% |
| 2013 | 7.68 Billion JPY | 39.71% |
| 2012 | 5.5 Billion JPY | -24.17% |
| 2011 | 7.25 Billion JPY | 70.22% |
| 2010 | 4.26 Billion JPY | 0.05% |
| 2009 | 4.26 Billion JPY | 183.82% |
| 2008 | 1.5 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 6.06 Billion JPY | -16.2% |
| 2024 Q1 | 7.71 Billion JPY | -49.74% |
| 2024 Q2 | 7.24 Billion JPY | -6.16% |
| 2023 FY | 15.35 Billion JPY | 47.14% |
| 2023 Q2 | 9.2 Billion JPY | -1.61% |
| 2023 Q1 | 9.35 Billion JPY | -10.32% |
| 2023 Q3 | 8.45 Billion JPY | -8.2% |
| 2023 Q4 | 15.35 Billion JPY | 81.64% |
| 2022 Q2 | 9.55 Billion JPY | 15.66% |
| 2022 Q1 | 8.25 Billion JPY | -2.31% |
| 2022 FY | 10.43 Billion JPY | 23.43% |
| 2022 Q4 | 10.43 Billion JPY | -1.74% |
| 2022 Q3 | 10.61 Billion JPY | 11.17% |
| 2021 Q1 | 5.44 Billion JPY | -13.3% |
| 2021 FY | 8.45 Billion JPY | 34.72% |
| 2021 Q4 | 8.45 Billion JPY | 36.36% |
| 2021 Q3 | 6.19 Billion JPY | 12.84% |
| 2021 Q2 | 5.49 Billion JPY | 0.98% |
| 2020 Q3 | 6.23 Billion JPY | -5.37% |
| 2020 FY | 6.27 Billion JPY | 18.98% |
| 2020 Q4 | 6.27 Billion JPY | 0.68% |
| 2020 Q1 | 5.14 Billion JPY | -2.49% |
| 2020 Q2 | 6.58 Billion JPY | 28.05% |
| 2019 FY | 5.27 Billion JPY | -15.47% |
| 2019 Q3 | 5.66 Billion JPY | -15.11% |
| 2019 Q1 | 5.57 Billion JPY | -10.63% |
| 2019 Q2 | 6.67 Billion JPY | 19.68% |
| 2019 Q4 | 5.27 Billion JPY | -6.92% |
| 2018 Q4 | 6.23 Billion JPY | 14.13% |
| 2018 Q2 | 4.84 Billion JPY | 14.93% |
| 2018 Q1 | 4.21 Billion JPY | -0.85% |
| 2018 FY | 6.23 Billion JPY | 46.73% |
| 2018 Q3 | 5.46 Billion JPY | 12.81% |
| 2017 Q4 | 4.25 Billion JPY | -19.08% |
| 2017 FY | 4.25 Billion JPY | -38.18% |
| 2017 Q3 | 5.25 Billion JPY | -13.11% |
| 2017 Q2 | 6.04 Billion JPY | -6.64% |
| 2017 Q1 | 6.47 Billion JPY | -5.82% |
| 2016 FY | 6.87 Billion JPY | 38.0% |
| 2016 Q1 | 4.43 Billion JPY | -10.96% |
| 2016 Q4 | 6.87 Billion JPY | -1.56% |
| 2016 Q3 | 6.98 Billion JPY | -6.55% |
| 2016 Q2 | 7.47 Billion JPY | 68.47% |
| 2015 FY | 4.98 Billion JPY | -33.13% |
| 2015 Q3 | 6.16 Billion JPY | -12.52% |
| 2015 Q4 | 4.98 Billion JPY | -19.14% |
| 2015 Q2 | 7.04 Billion JPY | 0.41% |
| 2015 Q1 | 7.01 Billion JPY | -5.86% |
| 2014 Q3 | 6.85 Billion JPY | -2.6% |
| 2014 Q2 | 7.04 Billion JPY | -5.11% |
| 2014 FY | 7.45 Billion JPY | -3.03% |
| 2014 Q1 | 7.41 Billion JPY | -3.48% |
| 2014 Q4 | 7.45 Billion JPY | 8.69% |
| 2013 Q3 | 5.21 Billion JPY | -12.9% |
| 2013 Q4 | 7.68 Billion JPY | 47.42% |
| 2013 FY | 7.68 Billion JPY | 39.71% |
| 2013 Q1 | 6.37 Billion JPY | 15.9% |
| 2013 Q2 | 5.98 Billion JPY | -6.11% |
| 2012 FY | 5.5 Billion JPY | -24.17% |
| 2012 Q1 | 6.83 Billion JPY | -5.87% |
| 2012 Q2 | 6.35 Billion JPY | -6.99% |
| 2012 Q3 | 5.64 Billion JPY | -11.13% |
| 2012 Q4 | 5.5 Billion JPY | -2.54% |
| 2011 Q2 | 6.1 Billion JPY | 1.8% |
| 2011 Q3 | 4.73 Billion JPY | -22.46% |
| 2011 Q4 | 7.25 Billion JPY | 53.29% |
| 2011 FY | 7.25 Billion JPY | 70.22% |
| 2011 Q1 | 5.99 Billion JPY | 40.69% |
| 2010 FY | 4.26 Billion JPY | 0.05% |
| 2010 Q4 | 4.26 Billion JPY | 0.0% |
| 2010 Q2 | 4.08 Billion JPY | 0.0% |
| 2009 Q4 | 4.26 Billion JPY | 0.0% |
| 2009 Q2 | 1.84 Billion JPY | 0.0% |
| 2009 FY | 4.26 Billion JPY | 183.82% |
| 2008 Q4 | 1.5 Billion JPY | 0.0% |
| 2008 FY | 1.5 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 36.57 Billion JPY | 58.024% |
| Takeda Pharmaceutical Company Limited | 15108.79 Billion JPY | 99.898% |
| Sumitomo Pharma Co., Ltd. | 907.5 Billion JPY | 98.308% |
| Shionogi & Co., Ltd. | 1416.91 Billion JPY | 98.917% |
| Wakamoto Pharmaceutical Co.,Ltd. | 15.42 Billion JPY | 0.448% |
| Nippon Shinyaku Co., Ltd. | 263.4 Billion JPY | 94.172% |
| Kaken Pharmaceutical Co., Ltd. | 171.62 Billion JPY | 91.055% |
| Eisai Co., Ltd. | 1393.79 Billion JPY | 98.899% |
| Morishita Jintan Co., Ltd. | 17.18 Billion JPY | 10.656% |
| Hisamitsu Pharmaceutical Co., Inc. | 328.77 Billion JPY | 95.331% |
| Mochida Pharmaceutical Co., Ltd. | 158.8 Billion JPY | 90.332% |
| Fuso Pharmaceutical Industries,Ltd. | 76.46 Billion JPY | 79.921% |
| Nippon Chemiphar Co., Ltd. | 49.54 Billion JPY | 69.016% |
| Tsumura & Co. | 428.25 Billion JPY | 96.415% |
| Kissei Pharmaceutical Co., Ltd. | 260.92 Billion JPY | 94.116% |
| Torii Pharmaceutical Co., Ltd. | 133.43 Billion JPY | 88.494% |
| Towa Pharmaceutical Co., Ltd. | 430.65 Billion JPY | 96.435% |
| Fuji Pharma Co., Ltd. | 85.33 Billion JPY | 82.009% |
| Zeria Pharmaceutical Co., Ltd. | 150.53 Billion JPY | 89.802% |
| KYORIN Holdings, Inc. | 177.67 Billion JPY | 91.36% |
| Taiko Pharmaceutical Co.,Ltd. | 15.04 Billion JPY | -2.034% |
| Daito Pharmaceutical Co.,Ltd. | 77.7 Billion JPY | 80.244% |
| MedRx Co., Ltd | 2.05 Billion JPY | -648.15% |
| Mizuho Medy Co.,Ltd. | 18.94 Billion JPY | 18.979% |
| Solasia Pharma K.K. | 2.55 Billion JPY | -502.041% |
| Modalis Therapeutics Corporation | 2.02 Billion JPY | -657.779% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 93.31 Billion JPY | 83.548% |
| Sawai Group Holdings Co., Ltd. | 382.02 Billion JPY | 95.981% |
| Cyfuse Biomedical K.K. | 4.21 Billion JPY | -264.241% |
| Toho Holdings Co., Ltd. | 773.42 Billion JPY | 98.015% |
| Koa Shoji Holdings Co.,Ltd. | 32 Billion JPY | 52.031% |